Arterial hypertension is the most common risk factor for heart failure in the general population. 1 The progression of hypertensive left ventricular (LV) involvement toward heart failure includes serial structural abnormalities (mainly myocardial fibrosis) and geometric changes of the left ventricle-LV concentric remodelling and LV hypertrophy (LVH) with high LV mass/volume ratio-whose prognostic role is recognized. [2] [3] [4] In the presence of these abnormalities, parallel abnormalities of LV diastolic properties occur. These abnormalities are globally defined as LV diastolic dysfunction (DD). They include alterations of both relaxation and filling, 5,6 precede alterations of LV chamber systolic function and can per se induce symptoms/signs of heart failure even when ejection fraction (EF) is normal (heart failure with normal ejection fraction (HFNEF)). Noteworthy, compared to those with reduced systolic function, patients with HFNEF are more often female, older, and less predisposed to have coronary artery disease and more likely to have hypertension. 7 The growing interest for DD and HFNEF rises from the knowledge that ~60% of patients with heart failure have a normal or near normal EF. 7 The prevalence of HFNEF has increased over the last 15-year period-it possibly reflects also on the greater number of patients undergoing Doppler-echocardiographic examination-while the rate of death from this disorder remained unchanged. 8 Accordingly, diagnosis, prognosis, and therapeutic management of DD and HFNEF in hypertensive patients is a growing public health problem.
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Physiology of Diastole
The traditional definition of diastole (διαστολε = "expansion"), includes the part of the cardiac cycle starting at the aortic valve closure-when LV pressure falls below aortic pressure-and finishing at the mitral valve closure. A normal diastolic function is clinically defined as the capacity of the left ventricle to receive a filling volume and its ability to guarantee an adequate stroke volume, operating at a low pressure regimen. In descriptive terms, diastole can be divided in four phases:
1. Isovolumetric relaxation: This is the period occurring between the end of systolic ejection (aortic valve closure) and the opening of the mitral valve, when LV pressure continues its rapid fall, while LV volume remains constant. atrio-ventricular pressure, and stops when this gradient ends. This period represents a complex interaction between LV suction (active relaxation) and visco-elastic properties of the myocardium (compliance). 3. Diastasis: This occurs when LA and LV pressures are almost equal and LV filling is essentially maintained by the flow coming from pulmonary veins-with left atrium representing a passive conduit-with an amount depending on LV pressure, function of LV "compliance". 4. Atrial systole: This corresponds to LA contraction and ends at the mitral valve closure. This period depends on LV compliance and, to a lower extent, on pericardial resistance, atrial force, and atrio-ventricular synchronicity (electrocardiogram-derived PR interval).
Globally, LV filling is determined by interaction between LV filling pressure (LVFP) and filling properties, which in turn are regulated by extrinsic factors (mainly pericardial restraint and ventricular interaction) and by intrinsic factors such as chamber stiffness (cardiomyocytes and extracellular matrix), myocardial tone, chamber geometry, and wall thickness. Increased LVFP is the main physio-pathologic consequence of DD. It is determined by filling and passive properties of LV walls, and may be additionally controlled by incomplete LV relaxation and alterations of myocardial diastolic tone. Main morphological and functional correlates of DD include LV concentric geometry, LA enlargement and function, and pulmonary arterial hypertension.
UltrastrUctUral featUres of lv Diastolic DysfUnction in arterial hyPertension
The extracellular matrix, corresponding to fibrillar collagen, is important for both myocardial contraction and relaxation processes. It facilitates the arrangement of the cardiomyocytes into the most suitable allocation for the development of force and shortening, giving a substantial support to the maintenance of an effective myocardial performance. 9 The hypertensivederived LV remodelling is accompanied by changes of both myocardial cell factors and of extracellular matrix where fibroblast proliferation, collagen network alteration, and increase in interstitial/perivascular collagen are strongly promoted by renin-angiotensin-aldosterone system. 10 Extracellular matrix undergoes an intense turnover due to metalloproteases, proteolytic enzymes activated by several factors including BNP, and tissue inhibitors counterbalancing the activity of metalloproteases. 11 Myocardial fibrosis occurs because of an imbalance where collagen deposition prevails over its degradation. In this context, the total amount of collagen is not only a main determinant of DD but also distribution, configuration, disorganization of collagen fibers (crosshatching), and collagen type I/ collagen type III ratio plays an important role. 9
DoPPler-echocarDiograPhic Diagnosis of lv Diastolic DysfUnction
The physical examination of patients with HFNEF allows to collect the same signs occurring for systolic heart failure and even the thoracic X-ray cannot be useful to distinguish the two entities. Electrocardiogram can show signs of LVH mainly due to arterial hypertension. DD may be even asymptomatic and identified occasionally during a Doppler-echocardiographic examination. The diagnostic importance of this tool rises from the high feasibility of transmitral Doppler indexes of diastolic function (ratio between early (E) and late (atrial-A) ventricular filling velocity (E/A ratio), deceleration time, isovolumic relaxation time (IVRT)), shown even in studies on population, 12 and demonstrated to be satisfactory for serial evaluations over time. This traditional approach permits to recognize normal diastole as well as to classify the progression of DD from the pattern of abnormal relaxation (grade I of DD: E/A ratio <1 and prolonged deceleration time) until pseudonormal (grade II: E/A ratio >1 and intermediate values of deceleration time) and restrictive patterns (reversible and irreversible, grade III-IV respectively; E/A ratio >1.5 and shortened deceleration time). 13 However, a modern comprehensive assessment of diastolic function should be performed not by classifying the progression of DD but by estimating the degree of LVFP, a true determinant of symptoms/ signs and prognosis of heart failure. In order to achieve this goal the standard Doppler assessment of mitral inflow can be enriched with the following maneuvers and/or ultrasound tools: (i) valsalva maneuver applied to the same mitral inflow pattern, (ii) pulmonary venous flow pattern (duration of atrial reverse velocity), (iii) velocity flow propagation (the slope of the first aliasing velocity during early filling, measured from the mitral valve to the apex by color M-mode (Vp)), (iv) pulsed tissue Doppler of the mitral annuls (average of septal and lateral early diastolic (e′) velocity) 14, 15 (Table 1 ). All the indexes obtainable by these ultrasound evaluations have advantages and limitations. The pulmonary atrial reverse-transmitral A-duration difference is relatively age-independent and enables to identify patients even with elevated LV end-diastolic pressure but normal mean LA pressure, an initial stage of LVFP increase. Vp and pulsed tissue Doppler-derived e′ are relatively load independent, characterize well LV relaxation and can, therefore, be used to adjust the preload dependence of transmitral E velocity and to obtain an estimation of LVFP degree. In addition, e′ velocity is able to "read" the percentage of myocardial fibrosis, 16 primum movens of DD. Vp and E/Vp ratio are limited in hypertensive patients with LV concentric geometry-which can induce itself an increase of Vp-and in those with normal LV volumes and EF, who may present misleadingly normal Vp despite increased LVFP. Valsalva maneuver applied to transmitral inflow and pulmonary venous flow have poor feasibility (60% and 80%, respectively) 17 whereas E/e′ ratio ( Figure 1 ) is performable in nearly 100% of the patients. 17 This index is also accurate in patients with sinus tachycardia 18 and atrial fibrillation 19 and has gained relevance in the clinical practice. The detection of LA enlargement can add further information in the intermediate, gray range of E/e′ ratio = 9-14, it being the expression of a chronic increase of LVFP, but cannot identify a sudden increase of LVFP. 15 Two-dimensional echocardiographic estimation of LA volume (average of LA volumes in apical 4-and 2-chamber view) reflects LA pressure much better than the simple LA antero-posterior diameter, has a recognized prognostic value 20 and can be used to categorize appropriately the magnitude of LA enlargement. Accordingly, recommendations for the evaluation of LV diastolic function have introduced LA volume in the algorithms built for the estimation of LVFP (Figure 2 ). 15 Further information on DD can be obtained by integrated back- E/e′ ≤8 Septal, lateral, or average 15 scatter, whose cardiac cycle-dependent variation is negatively correlated with the collagen deposition and thus with the extent of myocardial fibrosis, 21, 22 and by two-dimensional-derived speckle tracking echocardiography, which allows to quantify the multidirectional components of LV deformation (strain) either in systole or in diastole. 23 lv Diastolic DysfUnction in the hyPertensive setting All these concepts can be largely applied in arterial hypertension. Although systolic and diastolic function (mitral deceleration index) do not seem to improve the ability of LV mass in predicting cardiovascular (CV) risk did not improve significantly in 5,380 hypertensives (mean follow-up = 3.5 years), 24 the simple Doppler transmitral inflow pattern has been tested successfully in stratifying the hypertensive prognosis in epidemiologic studies. In the PIUMA study 25 an E/A ratio lower than that predicted individually by age and heart rate (approximately a pattern of abnormal relaxation) increased the risk of CV events (odds ratio 1.57, 95% confidence interval 1.1-2,18, P < 0.01) in a population of 1,839 hypertensives during a 11-year follow-up. Of interest, this prognostic value was independent on the effect of LV mass and 24-h blood pressure (BP). However, two other large epidemiological studies, 26, 27 both assessing populations with high prevalence of hypertension, revealed the intrinsic limitation of the simple transmitral inflow assessment with a "U-shaped" prognostic behavior of E/A ratio: prediction of CV events from E/A ratio <1 (pattern of abnormal relaxation) and >1.5 (likewise restrictive pattern) but no prognostic value of intermediate range of E/A ratio encompassing either patients with normal or unidentified, pseudonormal patterns (Figure 3) . In the first one, the Cardiovascular Health study 26 (2, 671 participants, mean follow-up = 5.2 years), E/A ratio <0.7 and >1.5 predicted incident heart failure even after adjusting for LV mass, age, BP, and level of stress-corrected LV systolic function. In the second one, the Strong Heart study 27 (3,008 American Indians, mean follow-up = 3 years), E/A ratio <0.6 was associated to a doubled increase of mortality risk-despite not independent on other covariates-while an E/A ratio >1.5 was associated to a threefold increase of cardiac mortality, independent on LV mass and EF. These two studies suggest: (i) the predisposition of elevated LVFP (restrictive pattern) to worse outcome, independently on LVH and systolic dysfunction, (ii) the need of distinguishing pseudonormal from normal pattern, which occurs when LVFP rises to increase the early filling caused by impaired relaxation and to maintain normal cardiac output. In this pseudonormal stage, patients often asymptomatic or pauci-symptomatic may receive benefit from more frequent follow-up and aggressive antihypertensive therapy. 28 Figure 4 shows the clinical progression of an old hypertensive patient from a pattern of abnormal relaxation toward a pseudonormal pattern which was unmasked by using E/e′ ratio. Of interest, the prognostic value of e′ is recognized in the hypertensive setting 29 and E/e′ ratio has demonstrated to be a prognosticator in 116 patients hospitalized for heart failure, including hypertensives with normal EF. 30 
correlates of Diastolic DysfUnction in arterial hyPertension
In the hypertensive heart alterations of myocardial composition and, thus of diastolic properties might be mediated by changes of coronary microcirculation. Today, coronary microcirculation may be evaluated by transthoracic echocardiography, by visualizing the distal left anterior descending artery [31] [32] [33] and measuring coronary flow reserve (CFR) (hyperemic to resting velocities ratio). [31] [32] [33] CFR has excellent concord- ance with intracoronary Doppler flow wire-derived CFR, 31 high feasibility, 32 and reproducibility. 32 In absence of epicardial coronary stenosis, impaired CFR indicates a coronary microvascular dysfunction. 33 DD is evident in hypertensives free of coronary artery disease when CFR impairment is also detectable. 34 This association is not surprising because coronary flow occurs predominantly during diastole. A change in the invasively measured time constant of LV isovolumic pressure fall (τ) is associated with decreased coronary flow even in patients without coronary artery disease. 35 Both reduced CFR and DD are associated with factors coexisting with hypertension such as insulin resistance, 36,37 LV concentric remodeling/ hypertrophy, 38,39 abnormalities of renin-angiotensin-aldosterone system, 40, 41 and endothelial dysfunction. 42, 43 We can, therefore, hypothesize that coronary microvascular damage plays a mechanistic role for DD or vice versa. Also the arterial stiffness has a great impact on DD through the ventricular-arterial coupling in different populations including hypertensives 44, 45 and elderly subjects. 46 A correlation between arterial stiffness and LA size was also observed in hypertensive patients. 47 Attempts have been made to establish the best arterial stiffness index in identifying preclinical DD: pulse wave velocity appears to be superior to central or brachial pulse pressure in older subjects. 48 The combination of DD and increased systolic ventricular-arterial stiffness strongly sustains the onset of HFNEF 49 but the presence of DD seems to be more important in the disease progression. 50, 51 The assessment of arterial stiffness and ventricular-arterial coupling is becoming a clinically relevant issue in hypertensive DD. 52 
lv systolic fUnction anD DD in arterial hyPertension
When myocardial fibrosis develops, the collagen accumulation increases myocardial stiffness and induces DD but also deprives cardiomyocytes of the skeleton needed for myocardial contraction. Therefore, it is easily understandable how the degree of myocardial fibrosis could be associated with the same extent to the impairment of both systolic and diastolic properties. 16 This was been firstly demonstrated in the hypertensive setting by an independent association found between IVRT and midwall fractional shortening, in presence of normal or supernormal EF 53 and even of electrocardiogram-derived LVH. 54 By using two-dimensional speckle tracking echocardiography, early impairment of global longitudinal strain (GLS) was observed in young hypertensives 55 and even in prehypertensive stages. 56 A relation between reduced GLS and increased E/e′ ratio was also detected in juvenile hypertension. 55 EF is a rather insensitive indicator of true myocardial contractility and subclinic alterations of LV systolic function are already overt in HFNEF. 57, 58 Evidences by speckle tracking echocardiography suggest that GLS and global radial systolic strain are reduced in HFNEF whereas preserved LV torsion and circumferential strain allow to maintain EF in the normal range. 59, 60 Accordingly, GLS progressively deteriorates in hypertensive patients from New York Heart Association I-IV class while LV circumferential systolic impairment appears in New York Heart Association III-IV classes. 61 GLS is a powerful predictor of cardiac events and a better prognostic parameter than EF in heart failure. 62 
theraPeUtic ManageMent of Diastolic DysfUnction in arterial hyPertension
The objectives of the therapeutic management of DD in the hypertensive setting include the improvement of hemodynamic conditions, by reducing both preload and afterload. The volume overload, such to induce episodes of acute heart failure, can be prevented or reduced by a moderate diuretic administration or by low salt diet. 63 Drugs acting on renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), appear conceptually to be the optimal drugs for the treatment of DD because they reduce both afterload and preload, induce reversal of LV concentric geometry, regression of LVH and decrease of myocardial fibrosis. 64 Experimental data suggest a synergistic attenuation of myocardial fibrosis (significant decrease in total collagen concentration, ratio of collagen type I to type III, and collagen crosslinking) by combining ACEIs and ARBs. 65 The clinical effect In the lower panels, the patient refers for a control after 6 months: the transmitral ratio between early and late ventricular filling velocity (E/a ratio) is 1.32 and only the transmitral early diastolic velocity to pulsed tissue Doppler-derived annular early diastolic velocity ratio (E/e′) (e′ of the septal annulus) = 15.2 allows to diagnose a pseudonormal pattern.
of ARBs on DD has been assessed in the recent years. Long-term treatment with valsartan improved both cyclic variation of myocardial integrated backscatter signal and DD in 43 hypertensives with normal EF. 66 Irbesartan, but not atenolol, induced parallel changes of circulating levels of the carboxy-terminal propeptide of procollagen type I (an index of collagen type I synthesis) and of IVRT 67 and reduced E/e′ ratio 68 in uncomplicated hypertensives. The regression of LVH induced by 12-month telmisartan therapy was accompanied by a parallel shortening of IVRT and decrease of LA volume. 69 In the VALIDD (Valsartan in Diastolic Dysfunction) study, 38-week valsartan therapy, added to concomitant antihypertensive agents, induced a significantly greater improvement of IVRT (P = 0.03) and of systolic velocity (s′) of the mitral annulus (P < 0.02) in comparison with matched placebo in hypertensives with DD (e′ velocity <10 cm/s in patients aged 45-54 years, <9 cm/s for age 55-65 years, <8 cm/s for age >65 years). 70 In the Hong Kong Diastolic Heart Failure study, the addition of ramipril or irbesartan to diuretics resulted in lower N-terminal prohormone of brain natriuretic peptide levels and higher annular s′ and e′ velocities. 71 The novel renin inhibitors aliskiren showed beneficial effects on myocardial remodeling in experimental studies 72 and efficacy in reducing LV mass of hypertensives with LVH 73 but its influence on DD has not been tested in the clinical setting. Also the antifibrotic effects of aldosterone antagonists might be a valuable strategy in treating hypertensive-derived DD. Spironolactone has been demonstrated to be effective in reducing myocardial fibrosis 74 and canrenone in improving DD in arterial hypertension. 75 Eplerenone attenuated the increase in procollagen type-III aminoterminal peptide at 12 months but was associated with only modest effect on DD, without any impact on clinical symptoms/signs or brain natriuretic peptide. 76 Results from ongoing trials using these drugs are expected.
Tachycardia and atrial fibrillation are two determinants of DD, also able to induce or worsen signs/symptoms in HFNEF. Lower heart rate induces prolongation of LV filling time, allowing to counterbalance the resistance to the diastolic inflow of a stiffened left ventricle. The heart rate control is, therefore, an important objective of management of DD. β-Blockers and calcium antagonist verapamil 77 can be useful. The selective β-blocker atenolol increased transmitral E/A ratio in 115 hypertensives with LVH. 78 Last generation β-blockers (carvedilol, nebivolol), which has vasodilation activity, could be conceptually indicated for the management of DD. In the SWEDIC (Swedish Doppler-Echocardiographic) study 6-month carvedilol therapy improved E/A ratio in comparison with marched placebo, especially in presence of higher baseline heart rate. 79 It seems, therefore, that the key feature in this study was heart rate reduction, which could also be achieved with other β-blocking agents. In another study, after 6-month therapy, nebivolol much more than atenolol induced increase of E/A ratio and reduction of "wedge" pressure, both at rest and during exercise, in 26 patients with HFNEF. 80 Potential methodological limitation of this study include, however, the poor sample size and the higher heart rate at baseline and during treatment in the atenolol group. Worthy of note, nebivolol reduced pulse wave velocity 81 and improved LVFP as well as CFR in uncomplicated hypertensives. 82 The association found between CFR increase and LVFP reduction indicates a possible common denominator between improvement of coronary microcirculation and myocardial stimulation of nitric oxide release on LV function induced by the drug. 82 The use of statins in the setting of DD, for treatment of either DD or overt HFNEF, is an area of research interest with practical clinical implications 83 and future development.
Based on experimental observations, novel drugs such as ivrabadine, 84 an I(f) inhibitor acting primarily on the sinoatrial node, and ranolazine, 85 which inhibits late I(Na), and reduces intracellular (Na + )(i) and diastolic (Ca 2+ )(i) overload improving myocardial relaxation, appear very promising for the treatment of DD but clinical studies with these drugs are still lacking. No rationale exists about the use of digoxin for the therapy of DD. A clinical trial failed to demonstrate the effect of digoxin on mortality in patients with HFNEF and normal sinus rhythm. 86 oUtcoMe registries anD clinical trials on heart failUre with norMal ejection fraction In HNEF registries, the effect of therapy on mortality resulted controversial [87] [88] [89] [90] (Table 2) . Of note, none of these registries provided information about either LV geometry or diastolic indexes.
In the last 15 years, pharmaceutical industry organized clinical trials to evaluate the prognostic impact of several drugs (ACEIs, ARBs, and β-blockers) on HFNEF. Vasodilator in heart failure therapy: enalapril vs. hydralazine/isosorbide dinitrate study 91 and Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors in elderly patients 92 cannot be considered true trials on HFNEF because the chosen baseline values of EF for patients selection were >35%. Well established echo-derived normal cut-off points of EF are, in fact, ≥55%. 93 The three remaining studies (Candesartan in Heart Failure-Assessment of Reduction in MortalityPreserved, PEP-CHF, and I-PRESERVE) dealt better with the issue. CHARM-Preserved (Candesartan in Heart FailureAssessment of Reduction in Mortality) study 94 did not show an improvement of the primary outcome (CV death or admission to hospital for heart failure) but only a mild reduction of hospitalization rate with candesartan in comparison with placebo. PEP-CHF (Perindopril in Elderly People with Chronic Heart Failure) study 95 compared perindopril (4 mg daily) and placebo in elderly patients (≥70 years) with evidence of LVH, LA dilation and abnormal LV filling pattern but did not show any difference in mortality and hospitalization for heart failure. I-PRESERVE trial 96 enrolled patients ≥60 years, randomly assigned to irbesartan (300 mg daily) or placebo but mortality or hospitalization rates for CV causes were not improved by irbesartan. Important methodological concerns of these three trials involve again identification and recruitment of HNEF patients. Mainly, the cut-off point of EF was lower than 55%, LV geometry was often eccentric and a variable proportion of patients had an ischemic origin. 97 In addition, poor or no information on LV diastolic function was available ( Table 3) .
clinical aPProach to the treatMent of Diastolic DysfUnction in arterial hyPertension
The recommended pharmacological management of DD in hypertensive patients should correspond first of all to BP lowering. In the VALIDD study, BP reduction-obtained by 87 Massie et al. 88 Tribouilloy et al. 89 Hernandez et al. 90 Number ACEI, angiotensin-converting enzyme inhibitor; CAD, coronary artery disease; CI, confidence interval; EF, ejection fraction; HF, heart failure; HFNEF, heart failure with normal ejection fraction; HTN, hypertension; HR, hazard ratio; LV, left ventricular; MI, myocardial infarction. either valsartan or agents that did not interrupt the renin system (about 40% of patients treated with a β-blocker, which suppresses renin secretion)-was the main determinant of DD improvement (annular e′ velocity) irrespective of antihypertensive agents used ( Figure 5) . 70 This finding is in agreement with an experience in which the achievement of a good BP control (by candesartan 16 mg or bendroflumethiazide 2.5 mg) and the enhancement of LV systolic function induced an increase of e′ velocity only after 3 months. 98 A very recent study compared the effect of intensive antihypertensive treatment (systolic BP target <130 mm Hg) and standard treatment (systolic BP target <140 mm Hg) in 228 hypertensive patients with uncontrolled hypertension over a follow-up period of 24 weeks: the degree of e′ velocity was associated with the extent of systolic BP reduction, and patients with the lowest achieved systolic BP had the highest final e′ velocity. 99 The best management should also include the attempt in reducing LV mass and normalizing LV geometry. Long-term (9-12 months) pharmacotherapy with β-blockers, calcium channel blockers, or ACEI reduced LVH by 8-14%, with an effect which was parallel to a marked improvement in CFR and DD. 100 In the Losartan Intervention For Endpoint reduction study the beneficial effect induced by 1-year therapy with atenolol or losartan on LV geometry (reduced rate of LV concentric remodeling and LVH) 101 was associated with a similar extent to LV filling improvement (reduced rate of abnormal and likewise pseudonormal/restrictive pattern).
conclUsions anD PersPectives
The progression of hypertensive involvement toward heart failure includes LV geometric changes and DD. Comprehensive assessment of DD should be performed not by simply classifying DD progression but by estimating LV FP degree, a true determinant of symptoms and prognosis. The practitioner approach to hypertensive patient with DD should correspond to BP lowering and to the attempt of reducing LV mass and normalizing LV geometry. Prospective studies with well-defined entry criteria ("true" normal EF, LV concentric geometry, standardized assessment of LV diastolic function) are needed to establish whether this approach could reflect a better prognosis in patients with arterial hypertension.
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